000166579 001__ 166579
000166579 005__ 20240917140552.0
000166579 0247_ $$2doi$$a10.2337/db19-0659
000166579 0247_ $$2pmid$$apmid:33239449
000166579 0247_ $$2ISSN$$a0012-1797
000166579 0247_ $$2ISSN$$a1939-327X
000166579 0247_ $$2altmetric$$aaltmetric:95011416
000166579 037__ $$aDKFZ-2020-03022
000166579 041__ $$aeng
000166579 082__ $$a610
000166579 1001_ $$aChen, Jessy$$b0
000166579 245__ $$aCaM Kinase II-δ is Required for Diabetic Hyperglycemia and Retinopathy but not Nephropathy.
000166579 260__ $$aAlexandria, Va$$bAssoc.$$c2021
000166579 3367_ $$2DRIVER$$aarticle
000166579 3367_ $$2DataCite$$aOutput Types/Journal article
000166579 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726574730_16365
000166579 3367_ $$2BibTeX$$aARTICLE
000166579 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166579 3367_ $$00$$2EndNote$$aJournal Article
000166579 500__ $$a2021 Feb;70(2):616-626
000166579 520__ $$aType 2 diabetes has become a pandemic and leads to late diabetic complications of organs including kidney and eye. Lowering hyperglycemia is the typical therapeutic goal in clinical medicine. However, hyperglycemia may only be a symptom of diabetes but not the sole cause of late diabetic complications, Instead, other diabetes-related alterations could be causative. Here, we studied the role of CaM Kinase II δ (CaMKIIδ) that is known to be activated through diabetic metabolism. CaMKIIδ is expressed ubiquitously and might therefore affect several different organ systems. We crossed diabetic leptin receptor mutant mice to mice lacking CaMKIIδ globally. Remarkably, CaMKIIδ-deficient diabetic mice did not develop hyperglycemia. As potential underlying mechanisms, we provide evidence for improved insulin sensing with increased glucose transport into skeletal muscle but also reduced hepatic glucose production. Despite normoglycemia, CaMKIIδ-deficient diabetic mice developed the full picture of diabetic nephropathy but diabetic retinopathy was prevented. We also unmasked a retina-specific gene expression signature that might contribute to CaMKII-dependent retinal diabetic complications. These data challenge the clinical concept of normalizing hyperglycemia in diabetes as a causative treatment strategy for late diabetic complications and call for a more detailed analysis of intracellular metabolic signals in different diabetic organs.
000166579 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000166579 588__ $$aDataset connected to CrossRef, PubMed,
000166579 7001_ $$aFleming, Thomas$$b1
000166579 7001_ $$aKatz, Sylvia$$b2
000166579 7001_ $$aDewenter, Matthias$$b3
000166579 7001_ $$aHofmann, Kai$$b4
000166579 7001_ $$aSaadatmand, Alireza$$b5
000166579 7001_ $$aKronlage, Mariya$$b6
000166579 7001_ $$aWerner, Moritz P$$b7
000166579 7001_ $$aPokrandt, Bianca$$b8
000166579 7001_ $$aSchreiter, Friederike$$b9
000166579 7001_ $$aLin, Jihong$$b10
000166579 7001_ $$aKatz, Daniel$$b11
000166579 7001_ $$aMorgenstern, Jakob$$b12
000166579 7001_ $$aElwakiel, Ahmed$$b13
000166579 7001_ $$aSinn, Peter$$b14
000166579 7001_ $$0P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aGröne, Hermann-Josef$$b15
000166579 7001_ $$aHammes, Hans-Peter$$b16
000166579 7001_ $$aNawroth, Peter P$$b17
000166579 7001_ $$aIsermann, Berend$$b18
000166579 7001_ $$aSticht, Carsten$$b19
000166579 7001_ $$aBrügger, Britta$$b20
000166579 7001_ $$aKatus, Hugo A$$b21
000166579 7001_ $$aHagenmueller, Marco$$b22
000166579 7001_ $$aBacks, Johannes$$b23
000166579 773__ $$0PERI:(DE-600)1501252-9$$a10.2337/db19-0659$$gp. db190659 -$$n2$$p616-626$$tDiabetes$$v70$$x1939-327X$$y2021
000166579 909CO $$ooai:inrepo02.dkfz.de:166579$$pVDB
000166579 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000166579 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000166579 9141_ $$y2021
000166579 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIABETES : 2018$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-29
000166579 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDIABETES : 2018$$d2020-08-29
000166579 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x0
000166579 980__ $$ajournal
000166579 980__ $$aVDB
000166579 980__ $$aI:(DE-He78)G130-20160331
000166579 980__ $$aUNRESTRICTED